221 related articles for article (PubMed ID: 30634956)
1. Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.
Wang J; Yu M; Xu J; Cheng Y; Li X; Wei G; Wang H; Kong H; Xie W
J Biomed Sci; 2019 Jan; 26(1):6. PubMed ID: 30634956
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
Xu J; Wang J; Cheng Y; Li X; He M; Zhu J; Han H; Wei G; Kong H; Xie W; Wang H; Zuo X
Biomed Res Int; 2018; 2018():1864107. PubMed ID: 29607314
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension.
Xu J; Wang J; He M; Han H; Xie W; Wang H; Kong H
Lab Invest; 2018 Oct; 98(10):1333-1346. PubMed ID: 29789684
[TBL] [Abstract][Full Text] [Related]
4. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
6. A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
Kohashi K; Hiromura M; Mori Y; Terasaki M; Watanabe T; Kushima H; Shinmura K; Tomoyasu M; Nagashima M; Hirano T
J Atheroscler Thromb; 2016; 23(4):441-54. PubMed ID: 26549734
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
8. Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.
Zhou X; Huang CH; Lao J; Pocai A; Forrest G; Price O; Roy S; Kelley DE; Sullivan KA; Forrest MJ
Cardiovasc Diabetol; 2015 Mar; 14():29. PubMed ID: 25888997
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 response to whey protein is less diminished by dipeptidyl peptidase-4 in comparison with responses to dextrin, a lipid and casein in rats.
Shimizu Y; Hara H; Hira T
Br J Nutr; 2021 Feb; 125(4):398-407. PubMed ID: 32713353
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
[TBL] [Abstract][Full Text] [Related]
11. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Hirano T; Mori Y
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
[TBL] [Abstract][Full Text] [Related]
12. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.
Al-Awar A; Almási N; Szabó R; Takacs I; Murlasits Z; Szűcs G; Török S; Pósa A; Varga C; Kupai K
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340421
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
14. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.
Liu L; Liu J; Tian XY; Wong WT; Lau CW; Xu A; Xu G; Ng CF; Yao X; Gao Y; Huang Y
Antioxid Redox Signal; 2014 Oct; 21(11):1571-81. PubMed ID: 24328731
[TBL] [Abstract][Full Text] [Related]
15. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
[TBL] [Abstract][Full Text] [Related]
16. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.
Dai Y; Dai D; Wang X; Ding Z; Mehta JL
Cardiovasc Drugs Ther; 2014 Oct; 28(5):425-32. PubMed ID: 25022544
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
19. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
20. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.
Morita A; Mukai E; Hiratsuka A; Takatani T; Iwanaga T; Lee EY; Miki T
Endocrine; 2016 Mar; 51(3):429-39. PubMed ID: 26349938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
